A Randomized, Placebo-controlled, Partially Blinded Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of BCG Revaccination, H4:IC31, and H56:IC31 in Healthy, HIV-1-Uninfected Adolescent Participants

Trial Profile

A Randomized, Placebo-controlled, Partially Blinded Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of BCG Revaccination, H4:IC31, and H56:IC31 in Healthy, HIV-1-Uninfected Adolescent Participants

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs H4IC (Primary) ; H56IC (Primary) ; BCG vaccine
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms A-042
  • Sponsors Aeras
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 11 Jul 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top